Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern
About the Authors: Felix Bongomin * E-mail: drbongomin@gmail.com Affiliation: Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda ORCID logo http://orcid.org/0000-0003-4515-8517 Introduction Tuberculosis (TB) caused by Mycobacterium tuberculosis comp...
Gespeichert in:
| Veröffentlicht in: | PLoS pathogens 2020-08, Vol.16 (8), p.e1008742-e1008742 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1008742 |
|---|---|
| container_issue | 8 |
| container_start_page | e1008742 |
| container_title | PLoS pathogens |
| container_volume | 16 |
| creator | Bongomin, Felix |
| description | About the Authors: Felix Bongomin * E-mail: drbongomin@gmail.com Affiliation: Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda ORCID logo http://orcid.org/0000-0003-4515-8517 Introduction Tuberculosis (TB) caused by Mycobacterium tuberculosis complex is the leading cause of death and diseases from a single infectious agent and continues to be a major global public health problem [1]. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp., and exclusion of alternative diagnoses, all present for at least 3 months [22,26]. Concurrent treatment of CPA and TB is very challenging due to the significant drug-drug interactions between anti-TB agents and the triazoles. Long-term oral antifungals with itraconazole at a dose of 400 mg/day or voriconazole at a dose of 400 mg/day administered for at least 6 months is the recommended first-line therapy for CPA associated with improvement in quality of life, relief of symptoms, and retardation of disease progression [38,39]. |
| doi_str_mv | 10.1371/journal.ppat.1008742 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2443615215</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A634243360</galeid><doaj_id>oai_doaj_org_article_b04266bfec6f4736984e072350143e92</doaj_id><sourcerecordid>A634243360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c661t-c8b2ff586fd7421000237f81c7aedb60a2ee27210ce09dc51e5f77d3c7461bc93</originalsourceid><addsrcrecordid>eNqVkk1v1DAQhiMEoqXwDxBE4gKHXfwVO-GAtKr4WKkCBOVsOc4465UTp3aC4N_jdNOqi3pBOTiaeeb1vOPJsucYrTEV-O3eT6FXbj0MalxjhErByIPsFBcFXQkq2MM7_yfZkxj3CDFMMX-cnVBSYsFZdZpdfvNxXI1TDUFPzkcbc70Lvrc6HybX-V6FP7mKA4TWuuv8u3zT59DNgb5NUO0SuwPlxl2ufa8h9E-zR0a5CM-W8yz7-fHD5fnn1cXXT9vzzcVKc47HlS5rYkxRctOk3pMFRKgwJdZCQVNzpAgAESmhAVWNLjAURoiGasE4rnVFz7KXB90hdSaXgURJGKMcFwQXidgeiMarvRyC7ZIf6ZWV1wEfWqnCaLUDWSNGOK8NaG6YoLwqGSBBaIEwo1CRpPV-uW2qO2g09GNQ7kj0ONPbnWz9LykYQ5zMAq8XgeCvJoij7GzU4JzqwU9z35QzhKuSJvTVP-j97haqVcmA7Y1P9-pZVG44ZUmPcpSo9T1U-hrobHoxMDbFjwreHBUkZoTfY6umGOX2x_f_YL8cs-zA6uBjDGBuZ4eRnHf6xqScd1ouO53KXtyd-23RzRLTv6cu8bk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443615215</pqid></control><display><type>article</type><title>Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><creator>Bongomin, Felix</creator><creatorcontrib>Bongomin, Felix</creatorcontrib><description>About the Authors: Felix Bongomin * E-mail: drbongomin@gmail.com Affiliation: Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda ORCID logo http://orcid.org/0000-0003-4515-8517 Introduction Tuberculosis (TB) caused by Mycobacterium tuberculosis complex is the leading cause of death and diseases from a single infectious agent and continues to be a major global public health problem [1]. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp., and exclusion of alternative diagnoses, all present for at least 3 months [22,26]. Concurrent treatment of CPA and TB is very challenging due to the significant drug-drug interactions between anti-TB agents and the triazoles. Long-term oral antifungals with itraconazole at a dose of 400 mg/day or voriconazole at a dose of 400 mg/day administered for at least 6 months is the recommended first-line therapy for CPA associated with improvement in quality of life, relief of symptoms, and retardation of disease progression [38,39].</description><identifier>ISSN: 1553-7374</identifier><identifier>ISSN: 1553-7366</identifier><identifier>EISSN: 1553-7374</identifier><identifier>DOI: 10.1371/journal.ppat.1008742</identifier><identifier>PMID: 32817649</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aspergillosis ; Aspergillus ; Biology and Life Sciences ; Biopsy ; Care and treatment ; Cavitation ; Chronic Disease - epidemiology ; Chronic obstructive pulmonary disease ; Complications and side effects ; Control ; Drug dosages ; Electronic mail ; Forecasts and trends ; Fungal infections ; HIV ; Human immunodeficiency virus ; Humans ; Immune response ; Immunoglobulins ; Immunology ; Infections ; Itraconazole ; Lung diseases ; Management ; Medicine and Health Sciences ; Microbiology ; Microscopy ; Nodules ; Pearls ; Public Health ; Pulmonary aspergillosis ; Pulmonary Aspergillosis - diagnosis ; Pulmonary Aspergillosis - epidemiology ; Pulmonary Aspergillosis - etiology ; Quality of life ; Risk factors ; Sarcoidosis ; Signs and symptoms ; Thorax ; Triazoles ; Tuberculosis ; Tuberculosis, Pulmonary - complications ; Tuberculosis, Pulmonary - diagnosis ; Voriconazole</subject><ispartof>PLoS pathogens, 2020-08, Vol.16 (8), p.e1008742-e1008742</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Felix Bongomin. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Felix Bongomin 2020 Felix Bongomin</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c661t-c8b2ff586fd7421000237f81c7aedb60a2ee27210ce09dc51e5f77d3c7461bc93</citedby><cites>FETCH-LOGICAL-c661t-c8b2ff586fd7421000237f81c7aedb60a2ee27210ce09dc51e5f77d3c7461bc93</cites><orcidid>0000-0003-4515-8517</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440622/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440622/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32817649$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bongomin, Felix</creatorcontrib><title>Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern</title><title>PLoS pathogens</title><addtitle>PLoS Pathog</addtitle><description>About the Authors: Felix Bongomin * E-mail: drbongomin@gmail.com Affiliation: Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda ORCID logo http://orcid.org/0000-0003-4515-8517 Introduction Tuberculosis (TB) caused by Mycobacterium tuberculosis complex is the leading cause of death and diseases from a single infectious agent and continues to be a major global public health problem [1]. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp., and exclusion of alternative diagnoses, all present for at least 3 months [22,26]. Concurrent treatment of CPA and TB is very challenging due to the significant drug-drug interactions between anti-TB agents and the triazoles. Long-term oral antifungals with itraconazole at a dose of 400 mg/day or voriconazole at a dose of 400 mg/day administered for at least 6 months is the recommended first-line therapy for CPA associated with improvement in quality of life, relief of symptoms, and retardation of disease progression [38,39].</description><subject>Aspergillosis</subject><subject>Aspergillus</subject><subject>Biology and Life Sciences</subject><subject>Biopsy</subject><subject>Care and treatment</subject><subject>Cavitation</subject><subject>Chronic Disease - epidemiology</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Complications and side effects</subject><subject>Control</subject><subject>Drug dosages</subject><subject>Electronic mail</subject><subject>Forecasts and trends</subject><subject>Fungal infections</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Infections</subject><subject>Itraconazole</subject><subject>Lung diseases</subject><subject>Management</subject><subject>Medicine and Health Sciences</subject><subject>Microbiology</subject><subject>Microscopy</subject><subject>Nodules</subject><subject>Pearls</subject><subject>Public Health</subject><subject>Pulmonary aspergillosis</subject><subject>Pulmonary Aspergillosis - diagnosis</subject><subject>Pulmonary Aspergillosis - epidemiology</subject><subject>Pulmonary Aspergillosis - etiology</subject><subject>Quality of life</subject><subject>Risk factors</subject><subject>Sarcoidosis</subject><subject>Signs and symptoms</subject><subject>Thorax</subject><subject>Triazoles</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - complications</subject><subject>Tuberculosis, Pulmonary - diagnosis</subject><subject>Voriconazole</subject><issn>1553-7374</issn><issn>1553-7366</issn><issn>1553-7374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqVkk1v1DAQhiMEoqXwDxBE4gKHXfwVO-GAtKr4WKkCBOVsOc4465UTp3aC4N_jdNOqi3pBOTiaeeb1vOPJsucYrTEV-O3eT6FXbj0MalxjhErByIPsFBcFXQkq2MM7_yfZkxj3CDFMMX-cnVBSYsFZdZpdfvNxXI1TDUFPzkcbc70Lvrc6HybX-V6FP7mKA4TWuuv8u3zT59DNgb5NUO0SuwPlxl2ufa8h9E-zR0a5CM-W8yz7-fHD5fnn1cXXT9vzzcVKc47HlS5rYkxRctOk3pMFRKgwJdZCQVNzpAgAESmhAVWNLjAURoiGasE4rnVFz7KXB90hdSaXgURJGKMcFwQXidgeiMarvRyC7ZIf6ZWV1wEfWqnCaLUDWSNGOK8NaG6YoLwqGSBBaIEwo1CRpPV-uW2qO2g09GNQ7kj0ONPbnWz9LykYQ5zMAq8XgeCvJoij7GzU4JzqwU9z35QzhKuSJvTVP-j97haqVcmA7Y1P9-pZVG44ZUmPcpSo9T1U-hrobHoxMDbFjwreHBUkZoTfY6umGOX2x_f_YL8cs-zA6uBjDGBuZ4eRnHf6xqScd1ouO53KXtyd-23RzRLTv6cu8bk</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Bongomin, Felix</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4515-8517</orcidid></search><sort><creationdate>20200801</creationdate><title>Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern</title><author>Bongomin, Felix</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c661t-c8b2ff586fd7421000237f81c7aedb60a2ee27210ce09dc51e5f77d3c7461bc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aspergillosis</topic><topic>Aspergillus</topic><topic>Biology and Life Sciences</topic><topic>Biopsy</topic><topic>Care and treatment</topic><topic>Cavitation</topic><topic>Chronic Disease - epidemiology</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Complications and side effects</topic><topic>Control</topic><topic>Drug dosages</topic><topic>Electronic mail</topic><topic>Forecasts and trends</topic><topic>Fungal infections</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Infections</topic><topic>Itraconazole</topic><topic>Lung diseases</topic><topic>Management</topic><topic>Medicine and Health Sciences</topic><topic>Microbiology</topic><topic>Microscopy</topic><topic>Nodules</topic><topic>Pearls</topic><topic>Public Health</topic><topic>Pulmonary aspergillosis</topic><topic>Pulmonary Aspergillosis - diagnosis</topic><topic>Pulmonary Aspergillosis - epidemiology</topic><topic>Pulmonary Aspergillosis - etiology</topic><topic>Quality of life</topic><topic>Risk factors</topic><topic>Sarcoidosis</topic><topic>Signs and symptoms</topic><topic>Thorax</topic><topic>Triazoles</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - complications</topic><topic>Tuberculosis, Pulmonary - diagnosis</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bongomin, Felix</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS pathogens</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bongomin, Felix</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern</atitle><jtitle>PLoS pathogens</jtitle><addtitle>PLoS Pathog</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>16</volume><issue>8</issue><spage>e1008742</spage><epage>e1008742</epage><pages>e1008742-e1008742</pages><issn>1553-7374</issn><issn>1553-7366</issn><eissn>1553-7374</eissn><abstract>About the Authors: Felix Bongomin * E-mail: drbongomin@gmail.com Affiliation: Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda ORCID logo http://orcid.org/0000-0003-4515-8517 Introduction Tuberculosis (TB) caused by Mycobacterium tuberculosis complex is the leading cause of death and diseases from a single infectious agent and continues to be a major global public health problem [1]. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp., and exclusion of alternative diagnoses, all present for at least 3 months [22,26]. Concurrent treatment of CPA and TB is very challenging due to the significant drug-drug interactions between anti-TB agents and the triazoles. Long-term oral antifungals with itraconazole at a dose of 400 mg/day or voriconazole at a dose of 400 mg/day administered for at least 6 months is the recommended first-line therapy for CPA associated with improvement in quality of life, relief of symptoms, and retardation of disease progression [38,39].</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32817649</pmid><doi>10.1371/journal.ppat.1008742</doi><orcidid>https://orcid.org/0000-0003-4515-8517</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1553-7374 |
| ispartof | PLoS pathogens, 2020-08, Vol.16 (8), p.e1008742-e1008742 |
| issn | 1553-7374 1553-7366 1553-7374 |
| language | eng |
| recordid | cdi_plos_journals_2443615215 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Public Library of Science (PLoS) |
| subjects | Aspergillosis Aspergillus Biology and Life Sciences Biopsy Care and treatment Cavitation Chronic Disease - epidemiology Chronic obstructive pulmonary disease Complications and side effects Control Drug dosages Electronic mail Forecasts and trends Fungal infections HIV Human immunodeficiency virus Humans Immune response Immunoglobulins Immunology Infections Itraconazole Lung diseases Management Medicine and Health Sciences Microbiology Microscopy Nodules Pearls Public Health Pulmonary aspergillosis Pulmonary Aspergillosis - diagnosis Pulmonary Aspergillosis - epidemiology Pulmonary Aspergillosis - etiology Quality of life Risk factors Sarcoidosis Signs and symptoms Thorax Triazoles Tuberculosis Tuberculosis, Pulmonary - complications Tuberculosis, Pulmonary - diagnosis Voriconazole |
| title | Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A52%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-tuberculosis%20chronic%20pulmonary%20aspergillosis:%20An%20emerging%20public%20health%20concern&rft.jtitle=PLoS%20pathogens&rft.au=Bongomin,%20Felix&rft.date=2020-08-01&rft.volume=16&rft.issue=8&rft.spage=e1008742&rft.epage=e1008742&rft.pages=e1008742-e1008742&rft.issn=1553-7374&rft.eissn=1553-7374&rft_id=info:doi/10.1371/journal.ppat.1008742&rft_dat=%3Cgale_plos_%3EA634243360%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443615215&rft_id=info:pmid/32817649&rft_galeid=A634243360&rft_doaj_id=oai_doaj_org_article_b04266bfec6f4736984e072350143e92&rfr_iscdi=true |